Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

BCN Research LLC

Neither a doctor nor a teaching hospital

Research payments

$361,820

32 payments

Through program year 2025, BCN Research LLC is reported as receiving $361,820 in research payments, across 32 payments.

By program year

3 rows
Year Kind Amount Payments
2025 Research $83,055 14
2024 Research $236,892 15
2023 Research $41,873 3

Breakdown

Who paid Research payments · program years 2023–2025
  1. AbbVie, Inc. $189,711 15 payments
  2. Ucb SA $98,361 6 payments
  3. Alexion Pharmaceuticals, Inc. $39,907 3 payments
  4. Takeda Pharmaceuticals U.S.A., Inc. $23,590 7 payments
  5. Genentech, Inc. $10,250 1 payment
Studies the money was for Research payments · program years 2023–2025
  1. Study of BOTOX Injections to Assess Change in Disease Symptoms in Adult Participants With Upper Limb Essential Tremor $165,637 12 payments
  2. A Phase 3B, Multicenter, Open-Label, Single-Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Zilucoplan in Participants With Generalized Myasthenia Gravis Switching From Intravenous Complement Component 5 Inhibitors to Subcutaneous Zilucoplan $51,324 3 payments
  3. A Phase 2, Randomized, Double Blind, Placebo Controlled Multicenter Study to Evaluate the Efficacy and Safety of ALXN2050 in Adult Participants with Generalized Myasthe $39,907 3 payments
  4. A MULTICENTER, OPEN-LABEL, outpatient STUDY TO EVALUATE THE SAFE AND EFFECTIVE USE OF A ZILUCOPLAN AUTO‑INJECTOR COMBINATION PRODUCT FOR SUBCUTANEOUS SELF-ADMINISTRATION BY STUDY PARTICIPANTS WITH GENERALIZED MYASTHENIA GRAVIS $27,423 1 payment
  5. A Phase 3 Single Arm Study to Evaluate the Efficacy, Safety, and Tolerability of Immune Globulin Subcutaneous (Human), 20% Solution with Recombinant Human Hyaluronidase (TAK-881) for the Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) $23,590 7 payments
  6. Study of Intramuscular Injections of ABBV-950 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Upper Limb Spasticity $14,500 1 payment
  7. A Phase 3B, Multicenter, Open-Label, Single-Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Zilucoplan in Participants With Generalized Myasthenia Gravis Switching From Intravenous Complement Component 5 Inhibitors to Subcut $11,000 1 payment
  8. Ocrevus Subcutaneous Study for Safety and Tolerability $10,250 1 payment
  9. M21-471 - Study of BOTOX Injections to Assess Change in Disease Symptoms in Adult Participants With Upper Limb Essential Tremor $9,574 2 payments
  10. A MULTICENTER, OPEN-LABEL, outpatient STUDY TO EVALUATE THE SAFE AND EFFECTIVE USE OF A ZILUCOPLAN AUTO?INJECTOR COMBINATION PRODUCT FOR SUBCUTANEOUS SELF-ADMINISTRATION BY STUDY PARTICIPANTS WITH GENERALIZED MYASTHENIA GRAVIS $8,614 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record